WallStSmart

Abbott Laboratories (ABT)vsIRIDEX Corporation (IRIX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 88502% more annual revenue ($46.59B vs $52.58M). ABT leads profitability with a 11.7% profit margin vs -6.2%. IRIX appears more attractively valued with a PEG of 0.94. ABT earns a higher WallStSmart Score of 52/100 (C-).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

IRIX

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 7.7Quality: 5.0
Piotroski: 4/9Altman Z: -2.51
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$108.03

$34.68 premium

UndervaluedFair: $73.35Overvalued
IRIXUndervalued (+75.3%)

Margin of Safety

+75.3%

Fair Value

$5.79

Current Price

$0.86

$4.93 discount

UndervaluedFair: $5.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

IRIX1 strengths · Avg: 8.0/10
PEG RatioValuation
0.948/10

Growing faster than its price suggests

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

IRIX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-126.4%2/10

ROE of -126.4% — below average capital efficiency

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : IRIX

The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : IRIX

The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while IRIX is a turnaround play — different risk/reward profiles.

IRIX carries more volatility with a beta of 0.64 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (52/100 vs 32/100) and 13.0% revenue growth. IRIX offers better value entry with a 75.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

IRIDEX Corporation

HEALTHCARE · MEDICAL DEVICES · USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?